Lack of Association between Human Papillomavirus Types 6 and 11 Genetic Variants and Cervical Abnormalities: The Ludwig-McGill Cohort Study.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
06 2019
Historique:
received: 23 01 2019
revised: 06 03 2019
accepted: 07 03 2019
pubmed: 15 3 2019
medline: 7 8 2020
entrez: 15 3 2019
Statut: ppublish

Résumé

Human papillomavirus (HPV) types 6 and 11 are mainly associated with the development of genital warts and recurrent respiratory papillomatosis. We examined intratypic genetic variability of both viral types with the development of cervical cytologic abnormalities in Brazilian women. We used PCR sequencing to characterize variants of HPVs 6 and/or 11 in cervical swabs from women in the Ludwig-McGill Cohort Study. We used a binomial generalized estimating equations (GEE) model with logit link to estimate odds ratios (OR) and 95% confidence intervals (CI) for the associations between HPV 6 and 11 variants and cytologic abnormalities. B1 and B3 HPV6 and A2 HPV11 variants were the most common isolates identified. Compared with HPV6-negative women, the ORs among women harboring HPV6 B1 or B3 variants were 6.3 (95% CI, 2.3-17.0) and 2.3 (95% CI, 0.6-9.7) for atypical cells of undetermined significance (ASCUS)/low squamous intraepithelial lesions (LSIL), respectively, and 1.7 (95% CI, 0.6-5.1) and 1.2 (95% CI, 0.3-4.7) for ASCUS/LSIL/high squamous intraepithelial lesions (HSIL). Respective ORs were 5.0 (95% CI, 1.7-14.6) and 2.8 (95% CI, 1.0-8.1) upon comparing women with HPV11 A2 variants to HPV11-negative women. All associations disappeared when adjusting for coinfections with high-risk HPV types. Our data do not support an association between low-risk HPVs 6 and 11 genetic variability and cervical abnormalities. Risk of cervical cytologic abnormalities is not affected by intratypic polymorphism in HPVs 6 and 11.

Sections du résumé

BACKGROUND
Human papillomavirus (HPV) types 6 and 11 are mainly associated with the development of genital warts and recurrent respiratory papillomatosis. We examined intratypic genetic variability of both viral types with the development of cervical cytologic abnormalities in Brazilian women.
METHODS
We used PCR sequencing to characterize variants of HPVs 6 and/or 11 in cervical swabs from women in the Ludwig-McGill Cohort Study. We used a binomial generalized estimating equations (GEE) model with logit link to estimate odds ratios (OR) and 95% confidence intervals (CI) for the associations between HPV 6 and 11 variants and cytologic abnormalities.
RESULTS
B1 and B3 HPV6 and A2 HPV11 variants were the most common isolates identified. Compared with HPV6-negative women, the ORs among women harboring HPV6 B1 or B3 variants were 6.3 (95% CI, 2.3-17.0) and 2.3 (95% CI, 0.6-9.7) for atypical cells of undetermined significance (ASCUS)/low squamous intraepithelial lesions (LSIL), respectively, and 1.7 (95% CI, 0.6-5.1) and 1.2 (95% CI, 0.3-4.7) for ASCUS/LSIL/high squamous intraepithelial lesions (HSIL). Respective ORs were 5.0 (95% CI, 1.7-14.6) and 2.8 (95% CI, 1.0-8.1) upon comparing women with HPV11 A2 variants to HPV11-negative women. All associations disappeared when adjusting for coinfections with high-risk HPV types.
CONCLUSIONS
Our data do not support an association between low-risk HPVs 6 and 11 genetic variability and cervical abnormalities.
IMPACT
Risk of cervical cytologic abnormalities is not affected by intratypic polymorphism in HPVs 6 and 11.

Identifiants

pubmed: 30867221
pii: 1055-9965.EPI-19-0114
doi: 10.1158/1055-9965.EPI-19-0114
pmc: PMC6548638
mid: NIHMS1523925
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1086-1088

Subventions

Organisme : NCI NIH HHS
ID : R01 CA070269
Pays : United States
Organisme : CIHR
ID : MA-13647
Pays : Canada
Organisme : CIHR
ID : MOP-49396
Pays : Canada
Organisme : CIHR
ID : CRN-83320
Pays : Canada

Informations de copyright

©2019 American Association for Cancer Research.

Références

Rev Panam Salud Publica. 1999 Oct;6(4):223-33
pubmed: 10572472
JAMA. 2001 Dec 26;286(24):3106-14
pubmed: 11754676
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1029-37
pubmed: 14578139
J Virol. 2014 Jul;88(13):7307-16
pubmed: 24741079
J Virol. 2016 May 12;90(11):5503-5513
pubmed: 27030261
J Infect Dis. 2017 Feb 15;215(4):559-565
pubmed: 28011919
J Gen Virol. 2017 Sep;98(9):2339-2342
pubmed: 28809141

Auteurs

Laura Sichero (L)

Center for Translational Investigation in Oncology, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil. laura.sichero@hc.fm.usp.br.

Mariam El-Zein (M)

Division of Cancer Epidemiology, McGill University, Montreal, Canada.

Silvaneide Ferreira (S)

Center for Translational Investigation in Oncology, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil.

Eduardo L Franco (EL)

Division of Cancer Epidemiology, McGill University, Montreal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH